Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Irinotecan as a Palliative Therapy for Metastatic Breast Cancer Patients after Previous Chemotherapy

  • Lan, Hai (Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhong Nan Hospital of Wuhan University) ;
  • Li, Yan (Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhong Nan Hospital of Wuhan University) ;
  • Lin, Cong-Yao (Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Clinical Cancer Study Center, Zhong Nan Hospital of Wuhan University)
  • Published : 2015.01.22
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This analysis was conducted to evaluate the efficacy and safety of irinotecan based chemotherapy for treatment of patients with metastatic breast cancer (MBC) who experienced disease progression after one to three chemotherapy regimens, including at least one anthracycline- or taxane-based. Methods: Clinical studies were identified using a predefined search strategy. Pooled response rates (RR) to treatment were calculated. Results: As irinotecan based regimens, 5 clinical studies which including 217 patients with refractory MBC were considered eligible for inclusion, with irinotecan, cisplatin, capecitabine, or TS-1. Systemic analysis suggested that, in all patients, pooled RR was 48.8% (106/217) with irinotecan based regimens. Thrombocytopenia and leukocytopenia were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related deaths occurred. Conclusion: This systemic analysis suggests that irinotecan based regimens are beneficial and safe for treating patients with MBC after other chemotherapy.

Keywords

References

  1. Carrick S, Parker S, Thornton CE, et al (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, CD003372.
  2. Chan S, Friedrichs K, Noel D, et al (1999). Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol, 17, 2341-54.
  3. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of $Loubo^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  4. Frasci G1, D'Aiuto G, Thomas R, et al (2005). Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients. Oncology, 68, 391-7. https://doi.org/10.1159/000086980
  5. Gale S, Croasdell G (2010). 28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics. IDrugs, 13, 139-41.
  6. Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
  7. Lee KS, Park IH, Nam BH, et al (2013).Phase II study of irinotecan plus capecitabine in anthracycline-and taxane-pretreated patients with metastatic breast cancer. Invest New Drugs, 31, 152-9. https://doi.org/10.1007/s10637-012-9824-8
  8. Liu LF, Desai SD, Li TK, et al (2000). Mechanism of action of camptothecin. Ann N Y Acad Sci, 922, 1-10.
  9. Liu YC, Zhou SB, Gao F, et al (2013).Phase II study on breast conservative surgery plus chemo-and radiotherapy in treating Chinese patients with early staged breast cancer.Asian Pac J Cancer Prev, 14, 3747-50. https://doi.org/10.7314/APJCP.2013.14.6.3747
  10. Moulder S, Valkov N, Neuger A et al (2008), Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer, 113, 2646-54. https://doi.org/10.1002/cncr.23916
  11. Otsuka H, Fujii T, Toh U, Iwakuma N, et al (2013). Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast Cancer.
  12. Perez EA, Hillman DW, Mailliard JA, et al (2004). Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol, 22, 2849-55. https://doi.org/10.1200/JCO.2004.10.047
  13. Sledge GW, Neuberg D, Bernardo P, et al (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol, 21, 588-92. https://doi.org/10.1200/JCO.2003.08.013
  14. Sparano JA, Wang M, Martino S, et al (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358, 1663-71. https://doi.org/10.1056/NEJMoa0707056
  15. Sparano JA, Makhson AN, Semiglazov VF, et al (2009). Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol, 27, 4522-9. https://doi.org/10.1200/JCO.2008.20.5013
  16. Stathopoulos GP, Tsavdaridis D, Malamos NA, et al (2005).Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol, 56, 487-91. https://doi.org/10.1007/s00280-005-1006-3
  17. Wang L, Huang XE, Cao J (2014).Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac J Cancer Prev, 15, 5597-600. https://doi.org/10.7314/APJCP.2014.15.14.5597
  18. Yang L, Parkin DM, Ferlay J, et al (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.
  19. Yu KD, Di GH, Wu J, et al (2007). Development and trends of surgical modalities for breast cancer in China: A review of 16-year data. Ann Surg Oncol, 14, 2502-9. https://doi.org/10.1245/s10434-007-9436-2